CFO Lars Sandström will leave Sobi during the summer 2012 to return to his
former employer Scania. The recruitment of a new CFO has been initiated.
Lars Sandström joined Sobi in 2010 and was appointed CFO in February 2011.
"We thank Lars for his contributions to Sobi and wish him well in his future
endeavors, says Geoffrey McDonough, President and CEO of Sobi.
For further information, please contact:
Åsa Stenqvist, Head of Communications
Tel.: +46 8 697 21 88
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 45 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 20 March, 2012 at 12.15 CET.